Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E.

Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Review.

2.

Managing Diversity To Eliminate Disparities: A Framework For Health.

Ko M, Sanders C, de Guia S, Shimkhada R, Ponce NA.

Health Aff (Millwood). 2018 Sep;37(9):1383-1393. doi: 10.1377/hlthaff.2018.0438.

PMID:
30179560
3.

Activating and inhibitory receptors expressed on innate lymphoid cells.

Guia S, Fenis A, Vivier E, Narni-Mancinelli E.

Semin Immunopathol. 2018 Jul;40(4):331-341. doi: 10.1007/s00281-018-0685-x. Epub 2018 May 22. Review.

PMID:
29789862
4.

Host resistance to endotoxic shock requires the neuroendocrine regulation of group 1 innate lymphoid cells.

Quatrini L, Wieduwild E, Guia S, Bernat C, Glaichenhaus N, Vivier E, Ugolini S.

J Exp Med. 2017 Dec 4;214(12):3531-3541. doi: 10.1084/jem.20171048. Epub 2017 Nov 15.

5.

Complement factor P is a ligand for the natural killer cell-activating receptor NKp46.

Narni-Mancinelli E, Gauthier L, Baratin M, Guia S, Fenis A, Deghmane AE, Rossi B, Fourquet P, Escalière B, Kerdiles YM, Ugolini S, Taha MK, Vivier E.

Sci Immunol. 2017 Apr 28;2(10). pii: eaam9628. doi: 10.1126/sciimmunol.aam9628.

6.

Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival.

Viant C, Guia S, Hennessy RJ, Rautela J, Pham K, Bernat C, Goh W, Jiao Y, Delconte R, Roger M, Simon V, Souza-Fonseca-Guimaraes F, Grabow S, Belz GT, Kile BT, Strasser A, Gray D, Hodgkin PD, Beutler B, Vivier E, Ugolini S, Huntington ND.

J Exp Med. 2017 Feb;214(2):491-510. doi: 10.1084/jem.20160869. Epub 2017 Jan 5.

7.

Manufacturing Natural Killer Cells as Medicinal Products.

Chabannon C, Mfarrej B, Guia S, Ugolini S, Devillier R, Blaise D, Vivier E, Calmels B.

Front Immunol. 2016 Nov 15;7:504. eCollection 2016. Review.

8.

Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.

Xu X, Narni-Mancinelli E, Cantoni C, Li Y, Guia S, Gauthier L, Chen Q, Moretta A, Vély F, Eisenstein E, Rangarajan S, Vivier E, Mariuzza RA.

J Mol Biol. 2016 Nov 6;428(22):4457-4466. doi: 10.1016/j.jmb.2016.09.011. Epub 2016 Sep 20.

PMID:
27663271
9.

Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance.

Guia S, Jaeger BN, Piatek S, Mailfert S, Trombik T, Fenis A, Chevrier N, Walzer T, Kerdiles YM, Marguet D, Vivier E, Ugolini S.

Sci Signal. 2011 Apr 5;4(167):ra21. doi: 10.1126/scisignal.2001608.

10.

Impact of β2 integrin deficiency on mouse natural killer cell development and function.

Crozat K, Eidenschenk C, Jaeger BN, Krebs P, Guia S, Beutler B, Vivier E, Ugolini S.

Blood. 2011 Mar 10;117(10):2874-82. doi: 10.1182/blood-2010-10-315457. Epub 2011 Jan 14.

PMID:
21239699
11.

Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients.

Schleinitz N, Chiche L, Guia S, Bouvier G, Vernier J, Morice A, Houssaint E, Harlé JR, Kaplanski G, Montero-Julian FA, Vély F.

PLoS One. 2009 Jul 16;4(7):e6264. doi: 10.1371/journal.pone.0006264.

12.

Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies.

Schleinitz N, Cognet C, Guia S, Laugier-Anfossi F, Baratin M, Pouget J, Pelissier JF, Harle JR, Vivier E, Figarella-Branger D.

Arthritis Rheum. 2008 Oct;58(10):3216-23. doi: 10.1002/art.23871.

13.

A role for interleukin-12/23 in the maturation of human natural killer and CD56+ T cells in vivo.

Guia S, Cognet C, de Beaucoudrey L, Tessmer MS, Jouanguy E, Berger C, Filipe-Santos O, Feinberg J, Camcioglu Y, Levy J, Al Jumaah S, Al-Hajjar S, Stephan JL, Fieschi C, Abel L, Brossay L, Casanova JL, Vivier E.

Blood. 2008 May 15;111(10):5008-16. doi: 10.1182/blood-2007-11-122259. Epub 2008 Mar 4.

PMID:
18319400
14.

Human NK cell education by inhibitory receptors for MHC class I.

Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E.

Immunity. 2006 Aug;25(2):331-42. Epub 2006 Aug 10.

15.

Massive inflammatory syndrome and lymphocytic immunodeficiency in KARAP/DAP12-transgenic mice.

Lucas M, Daniel L, Tomasello E, Guia S, Horschowski N, Aoki N, Figarella-Branger D, Gomez S, Vivier E.

Eur J Immunol. 2002 Sep;32(9):2653-63.

16.

Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice.

Tomasello E, Desmoulins PO, Chemin K, Guia S, Cremer H, Ortaldo J, Love P, Kaiserlian D, Vivier E.

Immunity. 2000 Sep;13(3):355-64.

17.

Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin.

André P, Spertini O, Guia S, Rihet P, Dignat-George F, Brailly H, Sampol J, Anderson PJ, Vivier E.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3400-5.

18.

The PEN5 epitope identifies an oligodendrocyte precursor cell population and pilocytic astrocytomas.

Figarella-Branger D, Daniel L, André P, Guia S, Renaud W, Monti G, Vivier E, Rougon G.

Am J Pathol. 1999 Oct;155(4):1261-9.

19.

Modulation of T-cell functions in KIR2DL3 (CD158b) transgenic mice.

Cambiaggi A, Darche S, Guia S, Kourilsky P, Abastado JP, Vivier E.

Blood. 1999 Oct 1;94(7):2396-402.

PMID:
10498612
20.

Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals.

André P, Brunet C, Guia S, Gallais H, Sampol J, Vivier E, Dignat-George F.

Eur J Immunol. 1999 Apr;29(4):1076-85.

21.

Engagement of natural cytotoxicity programs regulates AP-1 expression in the NKL human NK cell line.

Bernard K, Cambiaggi A, Guia S, Bertucci F, Granjeaud S, Tagett R, N'Guyen C, Jordan BR, Vivier E.

J Immunol. 1999 Apr 1;162(7):4062-8.

22.
23.

Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases.

Le Dréan E, Vély F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E.

Eur J Immunol. 1998 Jan;28(1):264-76. Erratum in: Eur J Immunol 1998 Mar;28(3):1122.

Supplemental Content

Support Center